Adaptimmune Therapeutics plc Gains 28.95%
Tue, Sep 07, 2021 at 05:30 PM
Adaptimmune Therapeutics plc (ADAP:NASDAQ) jumped higher at $6.37, a gain of 28.9%. The stock appeared on our News Catalysts scanner on Tue, Sep 07, 2021 at 12:48 PM in the 'AGREEMENT' category. From Fri, Aug 20, 2021, the stock recorded 60.00% Up Days and 54.55% Green Days
About Adaptimmune Therapeutics plc (ADAP:NASDAQ)
Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.
Top 10 Gainers:
- LWAC (LWAC:NASDAQ), 92.95%
- Mechel PAO (MTL:NYSE), 56.25%
- EFTR (EFTR:NASDAQ), 49.88%
- OG (OG:NYSE), 35.16%
- SRZN (SRZN:NASDAQ), 35.06%
- ZIOPHARM Oncology, Inc. (ZIOP:NASDAQ), 33.33%
- Adaptimmune Therapeutics plc (ADAP:NASDAQ), 28.95%
- LGL Systems Acquisition Corp. (DFNS:NYSE), 26.85%
- OPAD (OPAD:NYSE), 26.3%
- RNXT (RNXT:NASDAQ), 26.11%